6 recruiting. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 6 |
| Phase 2 | 3 | Recruiting 3 |
Follow Ischemia: new trials by email Literature Review of Ischemia trials Research Report on Ischemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) STX-1150 - Elevated LDL-C and High Cholesterol | Phase 1 | Recruiting | Monash University | 64 | 2026-06-30 | 2026-09-21 |
| Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability Psilocybin (Usona Institute) - Stroke, Chronic Stroke | Phase 1 | Recruiting | Johns Hopkins University | 20 | 2026-02-09 | 2026-02-13 |
| Accelerated rTMS vs. Sham for Stroke Apathy MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active), MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham), Brainsight Neuronavigation System - Apathy, Stroke | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 40 | 2025-08-08 | 2026-07-08 |
| A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. AK1967 (Invobenitug also known as Procizumab), Placebo - Shock, Cardiogenic | Phase 1 / Phase 2 | Recruiting | 4TEEN4 Pharmaceuticals GmbH | 90 | 2025-07-13 | 2026-09-14 |
| Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Packed Red Blood Cells (PRBCs) - Cardiogenic Shock, Extracorporeal Membrane Oxygenation | Phase 1 | Recruiting | University Hospital, Lille | 236 | 2023-09-18 | 2026-09-17 |
| Retina is a Marker for Cerebrovascular Heath Cilostazol - Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 100 | 2021-02-09 | 2026-08-03 |
Shock, Cardiogenic (2) · Stroke (2) · Anemia (1) · Atherosclerosis (1) · CADASIL (1) · Cardiovascular Diseases (1) · Cerebral Hemorrhage (1) · Cerebral Small Vessel Diseases (1) · Depression (1) · Hemiplegia (1) · Hemorrhagic Stroke (1) · Hypercholesterolemia (1) · Hypertension (1) · Infarction, Middle Cerebral Artery (1)
Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Vascular Diseases (6) · Cardiovascular Diseases (5) · Infarction (5) · Necrosis (5) · Brain Diseases (3) · Central Nervous System Diseases (3) · Cerebrovascular Disorders (3) · Heart Diseases (3) · Myocardial Ischemia (3) · Nervous System Diseases (3) · Brain Infarction (2) · Brain Ischemia (2)
Cilostazol (1) · Drug Delivery Systems (1) · Psilocybin (1) · Transcranial Magnetic Stimulation (1) · procizumab (1)
4TEEN4 Pharmaceuticals GmbH (1) · Johns Hopkins University (1) · Mayo Clinic (1) · Medical University of South Carolina (1) · Monash University (1) · University Hospital, Lille (1)
United States (3) · France (2) · Armenia (1) · Australia (1) · Belgium (1) · Czechia (1) · Germany (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Serbia (1) · Spain (1)
Alexandre Mebazaa, Professor (1) · David A. Morrow, MD, MPH (1) · Kevin Caulfield, PhD (1) · Lisa McTeague, PhD (1) · Michelle P Lin, MD, MPH (1) · Parneet Grewal, PhD (1) · Stephen Nicholls, MBBS, FRACP, PhD (1) · Victor Urrutia, M.D. (1)
PMID 20236457, PMID 21325598, PMID 23594433, PMID 24300013, PMID 24691607, PMID 25805204, PMID 26443879, PMID 26836806, PMID 28131429, PMID 30181084, PMID 30444173, PMID 30860564, PMID 31723612, PMID 33475735, PMID 42165327, PMID 9971864